Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Offerings

Stock Track

Nov 09, 2024

Shares of Hims & Hers Health Inc. (HIMS) plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.

According to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, which could ultimately be more affordable than traditional GLP-1 programs.

However, investors appear to be skeptical about the company's ability to maintain its weight-loss platform's growth trajectory if it can no longer offer compounded GLP-1 drugs, which have been in high demand due to the FDA's shortage list.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1125029696"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1125029696\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1125029696?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-09 03:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1125029696","market":"hk","top_or_hot":-1,"title":"Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Offerings","media":"Stock Track","content":"<p>Shares of Hims & Hers Health Inc. (HIMS) plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.</p>\n\n<p>According to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, which could ultimately be more affordable than traditional GLP-1 programs.</p>\n\n<p>However, investors appear to be skeptical about the company's ability to maintain its weight-loss platform's growth trajectory if it can no longer offer compounded GLP-1 drugs, which have been in high demand due to the FDA's shortage list.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Offerings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Hims & Hers Stock Plunges on Concerns Over Weight-Loss Offerings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-11-09 03:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of Hims & Hers Health Inc. (HIMS) plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.</p>\n\n<p>According to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, which could ultimately be more affordable than traditional GLP-1 programs.</p>\n\n<p>However, investors appear to be skeptical about the company's ability to maintain its weight-loss platform's growth trajectory if it can no longer offer compounded GLP-1 drugs, which have been in high demand due to the FDA's shortage list.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HIMS","symbol_name":"Hims & Hers Health Inc.","start_time":0,"source_url":"","article_id":"1125029696","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1125029696","pubTimestamp":1731093878,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Shares of Hims & Hers Health Inc.  plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.According to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, whi","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HIMS":"Hims & Hers Health Inc."},"translate_title":"股票追踪Hims&Hers股价因对减肥产品的担忧而暴跌","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"HIMS":1},"content_text":"Shares of Hims & Hers Health Inc. (HIMS) plummeted by 8.45% on Thursday morning, as concerns arose over the company's ability to maintain its weight-loss offerings if the shortage of GLP-1 drugs, a popular weight-loss medication, comes to an end.\nAccording to analysts at TD Cowen, who recently met with Hims & Hers management, the company believes it can provide a variety of weight-loss solutions, including oral medications, personalized dosages of compounded GLP-1s, branded GLP-1s, and liraglutide, which could ultimately be more affordable than traditional GLP-1 programs.\nHowever, investors appear to be skeptical about the company's ability to maintain its weight-loss platform's growth trajectory if it can no longer offer compounded GLP-1 drugs, which have been in high demand due to the FDA's shortage list.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}